282 related articles for article (PubMed ID: 30626790)
21. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
22. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
23. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract][Full Text] [Related]
24. Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm.
Kubota S; Tokunaga K; Umezu T; Yokomizo-Nakano T; Sun Y; Oshima M; Tan KT; Yang H; Kanai A; Iwanaga E; Asou N; Maeda T; Nakagata N; Iwama A; Ohyashiki K; Osato M; Sashida G
Nat Commun; 2019 Apr; 10(1):1653. PubMed ID: 30971697
[TBL] [Abstract][Full Text] [Related]
25. A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm with Orbital Tumor as the Initial Symptom.
Li P; Pang N; Li M; Xie J; Wang Y
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623681
[TBL] [Abstract][Full Text] [Related]
26. Profiling endogenous, environmental, and infectious disease mutational signatures in blastic plasmacytoid dendritic cell neoplasms.
Small C; Mukerjee S; Jangam D; Gollapudi S; Singh K; Jaye DL; Aung PP; Querfeld C; Yao K; Chisholm KM; Pullarkat S; Wang S; Gru A; Hussaini M; George TI; Ohgami RS
Int J Lab Hematol; 2023 Oct; 45(5):726-734. PubMed ID: 37282364
[TBL] [Abstract][Full Text] [Related]
27. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
28. Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis.
Suma S; Sakata-Yanagimoto M; Nguyen TB; Hattori K; Sato T; Noguchi M; Nannya Y; Ogawa S; Watanabe R; Fujimoto M; Nakamura N; Kusakabe M; Nishikii H; Kato T; Chiba S
Int J Hematol; 2018 Oct; 108(4):447-451. PubMed ID: 29705980
[TBL] [Abstract][Full Text] [Related]
29. Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Nasiri A; Lami A; Alhumaidi A; Madkhali A; Althaqib A; Aljarwan N; Alkharras R
Cureus; 2023 Apr; 15(4):e37016. PubMed ID: 37026111
[TBL] [Abstract][Full Text] [Related]
30. Azacitidine maintenance therapy for blastic plasmacytoid dendritic cell neoplasm allograft: A case report.
Tao LL; Wen HT; Wang ZY; Cheng J; Zhao L
World J Clin Cases; 2024 Jan; 12(1):136-141. PubMed ID: 38292626
[TBL] [Abstract][Full Text] [Related]
31. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm.
Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T
Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861
[TBL] [Abstract][Full Text] [Related]
32. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract][Full Text] [Related]
33. Treatment of blastic plasmacytoid dendritic cell neoplasm.
Sullivan JM; Rizzieri DA
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):16-23. PubMed ID: 27913457
[TBL] [Abstract][Full Text] [Related]
34. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
Xu R; Li M; Wu P; Deng C; Geng S; Huang X; Weng J; Du X
Hematology; 2021 Dec; 26(1):312-320. PubMed ID: 33706667
[TBL] [Abstract][Full Text] [Related]
35. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Sakamoto K; Katayama R; Asaka R; Sakata S; Baba S; Nakasone H; Koike S; Tsuyama N; Dobashi A; Sasaki M; Ichinohasama R; Takakuwa E; Yamazaki R; Takizawa J; Maeda T; Narita M; Izutsu K; Kanda Y; Ohshima K; Takeuchi K
Leukemia; 2018 Dec; 32(12):2590-2603. PubMed ID: 29795241
[TBL] [Abstract][Full Text] [Related]
36. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Wei Y; Zheng H; Lockyer PP; Darbaniyan F; Li Z; Kanagal-Shamanna R; Soltysiak KA; Yang H; Ganan-Gomez I; Montalban-Bravo G; Chien KS; Do KA; Daver N; Garcia-Manero G
Leuk Lymphoma; 2022 Dec; 63(13):3154-3164. PubMed ID: 36059252
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.
Wang W; Khoury JD; Miranda RN; Jorgensen JL; Xu J; Loghavi S; Li S; Pemmaraju N; Nguyen T; Medeiros LJ; Wang SA
Haematologica; 2021 Apr; 106(4):1047-1055. PubMed ID: 32241840
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.
Cheminant M; Bruneau J; Kosmider O; Lefrere F; Delarue R; Gaulard P; Radford I; Derrieux C; Hermine O; Lemonnier F
Br J Haematol; 2015 Mar; 168(6):913-6. PubMed ID: 25312805
[No Abstract] [Full Text] [Related]
39. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
40. [Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].
Manabe M; Okita J; Takakuwa T; Harada N; Aoyama Y; Kumura T; Ohta T; Furukawa Y; Mugitani A
Gan To Kagaku Ryoho; 2014 Jun; 41(6):781-4. PubMed ID: 25129095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
